 Angina, myocardial infarction, congestive heart failure or clinically significant valvular heart disease, arrhythmia, immunodeficiency including known HIV seropositive, ongoing or treatment-requiring chronic liver disease, active infection, oxygen requirement within two weeks prior to randomization, diffuse interstitial lung disease ILD or pulmonary fibrosis, second invasive malignancy treated with chemotherapy andor radiotherapy, invasive fungal infections requiring systemic treatment within 12 weeks of randomization. 